PPP1CC

Serine/threonine-protein phosphatase PP1-gamma catalytic subunit · P36873 · PPP1CC on Sugi Atlas →

4,161 patent compounds predicted against PPP1CC, 1,479 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Tautomycin Tautomycin (SCHEMBL83891) 0.71 11/20
SCHEMBL390763 SCHEMBL390763 1.00 3/20
SCHEMBL2332679 SCHEMBL2332679 1.00 3/20
SCHEMBL8758857 SCHEMBL8758857 1.00 3/20
SCHEMBL8080046 SCHEMBL8080046 0.84 3/20
SCHEMBL3191742 SCHEMBL3191742 0.71 3/20
SCHEMBL3497096 SCHEMBL3497096 0.71 3/20
Endothall Endothall (SCHEMBL55158) 0.68 3/20
Endothall Endothall (SCHEMBL3494764) 0.68 3/20
Endothall Endothall (SCHEMBL3495744) 0.68 3/20
Endothall Endothall (SCHEMBL8536404) 0.68 3/20
SCHEMBL1104061 SCHEMBL1104061 0.68 3/20
Endothall Endothall (SCHEMBL4353120) 0.65 3/20
SCHEMBL389760 SCHEMBL389760 0.65 3/20
SCHEMBL8758236 SCHEMBL8758236 0.65 3/20
SCHEMBL8758385 SCHEMBL8758385 0.65 3/20
SCHEMBL8968922 SCHEMBL8968922 0.64 3/20
Endothall Endothall (SCHEMBL8466779) 0.63 3/20
Endothall Endothall (SCHEMBL5933886) 0.60 3/20
SCHEMBL8649646 SCHEMBL8649646 0.59 3/20

Clinical trials — most relevant to PPP1CC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421 nanCOMPLETED
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Evaluating Changes in Skeletal Muscle Proteins Following Resistance Exercise and Single-Leg Disuse nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
The Effects of Whey vs. Collagen on MPS nanCOMPLETED
Phosphoproteomic Profile of Children With Down Syndrome nanCOMPLETED
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPP1CC binder may also engage these)

ProteinNameSimilarity
P63087 1.000 P63087 →
P63088 1.000 P63088 →
P36874 1.000 P36874 →
P61287 1.000 P61287 →
Q6NVU2 1.000 Q6NVU2 →
P62139 1.000 P62139 →
Q7SZ10 1.000 Q7SZ10 →
P62138 1.000 P62138 →
P62137 1.000 P62137 →
P13681 1.000 P13681 →
Q8WMS6 1.000 Q8WMS6 →
Q8MJ46 1.000 Q8MJ46 →
P61292 1.000 P61292 →
PPP1CA Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 1.000 landscape →
Q6GQL2 1.000 Q6GQL2 →
P62140 1.000 P62140 →
P62143 1.000 P62143 →
P22198 1.000 P22198 →
Q3T0E7 1.000 Q3T0E7 →
Q9UW86 1.000 Q9UW86 →
P48462 1.000 P48462 →
P48488 1.000 P48488 →
P62141 1.000 P62141 →
P62142 1.000 P62142 →
Q9M9W3 1.000 Q9M9W3 →
P62207 1.000 P62207 →
Q5I085 1.000 Q5I085 →
Q8MJ47 1.000 Q8MJ47 →
Q5R740 1.000 Q5R740 →
Q3SWW9 1.000 Q3SWW9 →